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Abstract 
 
Background: To evaluate the prevalence rates of non-amnestic neurological symptoms of 
autosomal dominant Alzheimer's disease (ADAD) in the DIAN Observational Study (DIAN–
OBS) and the published literature. Analyses were conducted to clarify the prevalence of 
neurological manifestations of ADAD mutation carriers as a group. 
 
Methods: Using the DIAN-OBS study database and 189 peer-reviewed publications on ADAD 
families, we extracted individual-level data on age of symptom onset, disease course from onset 
to death, and the presence of fourteen neurological findings that have been reported in association 
with ADAD and included symptomatic subjects only. The primary outcomes were the rates of 
various neurological symptoms and the contribution of age and specific mutations on the 
prevalence of the neurological symptoms. Analyses were done using descriptive statistics, 
comparisons of means and frequencies and multivariable linear regression. 
 
Findings: Our meta-analysis dataset includes 1228 affected individuals, with detailed clinical 
descriptions of 753. The DIAN–OBS dataset included 107 individuals with detailed clinical data. 
The most prevalent non-amnestic cognitive manifestations in DIAN were those typical of mild-
moderate Alzheimer’s disease, including visual agnosia (95% CI 45·7%–64·6%), aphasia (43·8%–
62·7%), and behavioral changes (51·5%–70·0%). The prevalence of non-amnestic cognitive 
manifestations from the published literature were (95% CI 3·9%–7·2%) for visual agnosia, (20%–
26%) for aphasia, and (28·4%–35·1%) for behavioral changes. Prevalence of non-cognitive 
neurological manifestations in DIAN was low, including myoclonus and spasticity (3·8%–15·0%), 
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seizures (0·5%–9·1%) and moderate for parkinsonism (5·3%–17·1%). Whereas, in the published 
literature the prevalence was (95% CI 16·6%–22·2% and 12·5%–17·6%) for myoclonus and 
spasticity, (10·1%–15·0%) for parkinsonism, and (17·4%–23·2%) for seizures. Age of onset 
appears to influence the prevalence of several non-cognitive manifestations in both groups, stroke 
being more prevalent at older ages of onset with motor symptoms being more prevalent at younger 
age of onset and at an older age of onset. Further, symptoms were overall more common in later 
clinical stages of disease.  
 
Interpretation: Comparing the prevalence of non-amnestic and non-cognitive clinical features in 
DIAN with the published literature indicates that previous reports of non-cognitive features are 
likely overestimated whereas DIAN identifies higher non-amnestic cognitive symptoms in 
addition to memory impairment. The non-cognitive clinical manifestations of AD appear to be in 
a minor fraction of mild-moderate ADAD and is likely influenced by disease severity, 
environmental and genetic factors in addition to genetic status. The results of this work clarify the 
clinical presentations of ADAD including the effects of age and disease stage. Attention to these 
neurologic symptoms and screening for ADAD mutations are warranted if present.  Future work 
is needed to determine the factors which cause these neurologic symptoms. 
 
 
Funding: National Institutes of Health (UF1AG032438), German Center for Neurodegenerative 
Diseases (DZNE), MRC Dementias Platform UK (MR/L023784/1 and MR/009076/1) and NIHR 
Queen Square Dementia Biomedical Research Unit. 
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Abbreviations: ADAD = autosomal dominant Alzheimer's disease; APOE = Apolipoprotein E; 
APP = amyloid precursor protein; CAA = Cerebral amyloid angiopathy; CDR = Clinical Dementia 
Rating; DIAN = Dominantly Inherited Alzheimer’s Network; DIAN-OBS = DIAN Observational 
Study; FAQ = Functional Activities Questionnaire; GDS = Geriatric Depression Scale; HIS = 
Hachinski Ischemic Score; MMSE = Mini-Mental Status Exam; PSEN1 = presenilin-1; PSEN2 = 
presenilin-2; UPDRS = Unified Parkinson’s disease rating scale; UDS = Uniform Data Set 
 
Introduction 
Autosomal dominant Alzheimer's disease (ADAD) is a rare, completely penetrant form of 
Alzheimer’s disease that typically presents at a much earlier age than sporadic forms of 
Alzheimer’s disease. Despite its rarity, ADAD has been used as a model for understanding 
pathological processes and developing potential therapies for sporadic Alzheimer's disease due to 
similarities in both clinical course and pathophysiology (for a comprehensive review, see Bateman 
et al, 20111). Although the majority of carriers of symptomatic mutations in the amyloid precursor 
protein (APP), presenilin-1 (PSEN1), or presenilin-2 (PSEN2) present with early amnestic 
symptoms2 similar to those with sporadic Alzheimer’s disease, a significant portion of individuals 
with ADAD have been reported to exhibit additional behavioral and neurologic deficits, such as 
seizures, myoclonus, spastic paraparesis, or visual disturbances, with remarkable diversity in age 
of onset, clinical presentation, and rate of progression1,3-5. The location of mutations within genes 
has also been shown to affect pathophysiology and age of onset, as is the case for presenilin-1 
mutations before and after codon 2006. As a consequence of the rarity of ADAD and the reported 
variability in presentation, it has been difficult to estimate the prevalence of neurological 
manifestations of ADAD mutation carriers as a group.  
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To this end, we aimed to better clarify the incidence and prevalence rates of non-amnestic 
manifestations of ADAD from a prospective global observational ADAD study– the Dominantly 
Inherited Alzheimer’s Network Observational Study (DIAN–OBS) – and also individual level data 
of symptomatic cases extracted from 189 published reports. Additionally, we aimed to assess 
relationships of these clinical manifestations with the age of symptom onset and the location of 
ADAD mutations within affected genes as this could provide important information on the 
pathophysiology of ADAD mutations. The DIAN–OBS findings complement the existing 
published literature by contributing uniform and extensive assessments in a prospective cohort 
with mild to moderate AD to the literature reports of pedigrees clinically followed to more 
advanced stages of dementia. The results of this work may help to clarify the clinical presentations 
of ADAD and hold implications for the structure and function of the presenilin proteins and APP.  
 
Methods 
The DIAN study is reviewed and approved by all participating sites Institutional/Ethical Review 
Boards (IRB). All participants (and as appropriate their legally authorized representatives) sign 
IRB-approved DIAN consent forms that include a statement informing participants that 
deidentified data will be shared with authorized investigators for future research following 
guidelines for preserving confidentiality through coded identifiers. 
 
Literature database: In an expansion of our previously reported ADAD meta-analysis dataset7, 
clinical data on 1335 carriers of 183 known pathogenic mutations in APP, PSEN1, and PSEN2 was 
collected from publications cited in the Alzheimer’s Disease/Frontotemporal Dementia Mutation 
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Database, the Alzheimer Research Forum database, and PubMed search results using the terms 
"dominant Alzheimer”, “dominant AD”, “ADAD”, “presenilin”, “PSEN1”, “PSEN2”, and “APP”. 
Genotype information, pedigree information, ages of onset and death, clinical descriptions of the 
disease course and symptomatology, and pathological findings for each affected individual were 
recorded, when available. Demographic characteristics of this population are provided in table 1.  
 
DIAN database: Analyses were performed on DIAN datafreeze 8. Participants in the DIAN 
observational study include families of carriers of mutations causing ADAD in APP, PSEN1 or 
PSEN28. Per standard DIAN protocols, each study participant and a collateral source underwent 
semi-structured interviews that included detailed demographics, medical history, and family 
history. All study staff underwent audiotape recordings of the clinical assessments at the beginning 
of the study and then every 10th participant to ensure compliance with the protocol and increase 
inter-rater reliability. In addition, each participant completed a physical and neurological 
examination conducted by a clinical evaluator who was blinded to the participant's mutation status. 
A total of 107 individuals were considered to be symptomatic at time of analysis, based upon 
having both a Clinical Dementia Rating sum of boxes (CDRsb) score9 greater than 0 and a known 
pathogenic ADAD mutation as confirmed by genetic testing using methods previously 
described10,11. Using data from these individuals, we constructed a database including age, gender, 
mutated gene, mutation type (including specific amino acid change of the mutation, eg, PSEN1 
E280A), APOE genotype, family history, medical history, list of medications, age of onset 
evaluation, physical exam, neurological exam, CDR (including supplemental boxes for behavior 
and language), Functional Activities Questionnaire (FAQ), Mini-Mental Status Exam (MMSE), 
Geriatric Depression Scale (GDS), Unified Parkinson’s disease rating scale (UPDRS), vascular 
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contributions to dementia/or history of stroke (Hachinski Ischemic Score, (HIS), clinical judgment 
of symptoms, clinician diagnosis, and psychometric battery summary.  
 
Individuals were assessed for the presence of non-amnestic cognitive or non-cognitive symptoms 
using neurological exams conducted during their initial visit and each visit thereafter and sections 
from the National Alzheimer's Coordinating Center's Uniform Data Set (UDS)12, paying specific 
attention to the health history (UDS A5, B2), UPDRS (UDS B3), and clinician judgment of 
symptoms (UDS B9). UPDRS scores were calculated based on review of performance in each of 
27 motor domains (eg, body bradykinesia, facial expressiveness, gait, etc), with a maximum 
possible score of 108. If an individual exhibited a specific symptom during any visit, that symptom 
was marked as "present". Demographic characteristics of this population are provided in table 1. 
A list of descriptions of the exact process used to extract this data is provided in supplemental table 
1.  
 
Subject selection: Only symptomatic individuals were studied. We included a total of 753 
individuals from literature reports and 107 from the DIAN Observational Study in our analysis 
(table 1). In the literature group, individuals were designated as symptomatic by the authors of the 
publication in which they are found, and their age of symptom onset was recorded when available. 
Length of follow up time in this group is defined as the time from age of onset until the individual 
either died or was lost to follow up. Age of onset was determined by clinician judgment as the age 
at which the individual began to exhibit cognitive decline, and years of follow up is calculated by 
subtracting the individual's age of onset from their age at the latest visit. Those APP mutations 
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with predominant cerebral amyloid angiopathy (CAA), ie, the Dutch mutation, were not included 
in this analysis as they may be associated with less uniform pathology. 
 
Statistical analysis: For the comparison between autosomal dominant and DIAN, we calculated 
the prevalence of a group of cognitive and non-cognitive symptoms in the literature database and 
the DIAN cohort, respectively. To compare symptom prevalence between mutations found in APP, 
PSEN1, and PSEN2, we constructed a generalized linear mixed model treating the mutated gene 
as a fixed effect, and including a unique identifier for family pedigree as a random effect, in order 
to take into account the impact of familial genetics. Age of onset was also included as a fixed 
effect. We did not specifically analyze the effect of APOE ε4 carrier status on disease course due 
to limitations in sample size. Additionally, we directly compared the symptom prevalence in 
carriers of PSEN1 mutations before and after codon 2006. We also explored the relationship 
between clinical severity as measured by CDR-SB and the frequency of clinical features in the 
DIAN–OBS group but were unable to perform a similar exploration in the literature group due to 
clinical ratings at time of non-amnestic symptoms not being reported in most. 
 
Role of the funding source: Data collection and sharing for this project was supported by The 
Dominantly Inherited Alzheimer’s Network (DIAN, UF1 AG032438) funded by the National 
Institute on Aging (NIA), the German Center for Neurodegenerative Diseases (DZNE), The MRC 
Dementias Platform UK (MR/L023784/1 and MR/009076/1) and NIHR Queen Square Dementia 
Biomedical Research Unit. This manuscript has been reviewed by DIAN Study investigators for 
scientific content and consistency of data interpretation with previous DIAN Study publications. 
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The corresponding author had full access to the data in the study and had final responsibility for 
the decision to submit for publication. 
 
Results 
Compared to the literature group, the DIAN Observation Study cohort has a significantly earlier 
average age of onset and shorter average follow up time (Table 1). Overall, 36 of the 107 
individuals in the DIAN–OBS displayed one or more abnormality on the neurological exam at any 
point during the time they were followed (figure 1). Significantly higher rates of cognitive 
symptoms were noted in the DIAN–OBS group than the literature group, including aphasia 
(57/107 (53%) vs. 173/753 (23%), p < 0·0001), visual agnosia (59/107 (55%) vs. 42/753 (5·6%), 
p < 0·0001), and behavioral/personality changes (65/107 (61%) vs. 239/753 (32%), p < 0·0001) 
(table 2). In contrast, motor symptoms such as myoclonus (10/107 (9·3%) vs. 146/753 (19%), p = 
0·0117) and recent/active seizures (3/107 (2·8%) vs. 153/753 (20·3%), p < 0·0001) were less 
common in the DIAN–OBS group compared to the literature group; corticobulbar deficits were 
marginally less common in DIAN–OBS (3/107 (2·8%) vs. 61/753 (8·1%), p= 0·051). The rate of 
cerebellar ataxia was higher in the DIAN–OBS group than the literature group (16/107 (15%) vs. 
23/753 (3·1%), p < 0·0001). The rates of parkinsonism were similar between DIAN–OBS and the 
literature group, (12/107 (11%) vs. 94/753 (12%), p = 0·71). Of the twelve individuals in DIAN 
who displayed parkinsonian symptoms, eleven were mildly symptomatic (UPDRS total score < 
36), and one was moderately symptomatic with a score of 58. In DIAN–OBS compared to the 
literature group the rate of spasticity was not significantly different (10/107, (9·3%) vs. 113/753 
(15%), p= 0·12). The rate of behavioral and personality changes was greater in the DIAN–OBS 
group compared to the literature group (65/107 (61%) vs. 239/753 (32%), p < 0·0001), but 
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hallucinations were similar and low (7/107 (7%) vs. 42/753 (6%), p= 0·69) in both groups. No 
individuals in the DIAN–OBS cohort have reported recent or active hemorrhagic stroke or 
ischemic stroke whereas the rate from the reported literature was low (55/753, 7·3%).  
 
We also examined the prevalence of behavioral and neurological symptoms in the reported 
literature, by mutated gene. In order to account for other genetic factors specific to the family and 
physiological changes as an individual ages, pedigree ID and age of onset were included as 
covariates (figure 2). The number of PSEN2 mutation carriers was too small to make meaningful 
comparisons when these covariates are taken into consideration. Compared to APP mutation 
carriers, PSEN1 mutation carriers as reported by published literature are significantly more likely 
to exhibit myoclonus (OR = 4·25, 95% CI [1·37, 13·2], p = 0·0125), corticobulbar deficits (OR = 
9·78, 95% CI [1·32, 72·4], p = 0·0257), and aphasia (OR = 3·76, 95% CI [1·33, 10·7], p = 0·0129); 
spasticity was also more common in PSEN1 mutation carriers (n=110 of 547) compared to APP 
mutation carriers (n=2 of 171). On the other hand, APP mutation carriers were significantly more 
likely to present with ischemic stroke (OR = 3·92, 95% CI [1·33, 11·6], p = 0·0135); a hemorrhagic 
stroke was also more common APP mutation carriers (n=29 of 171) compared to PSEN1 mutation 
carriers (n=2 of 547). There were no significant differences in the prevalence of parkinsonism, 
apraxia, visual agnosia, behavioral/personality changes, or hallucinations between the three groups 
in the literature. In contrast, there were no significant differences in the DIAN cohort in myoclonus, 
aphasia, or stroke.  
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Clinical stage of disease was also associated with an increased frequency of all clinical features, 
with the exception of corticobulbar deficits, with increasing disease severity as measured by CDR–
SB) in the DIAN–OBS (figure 3b). 
 
Age at symptom onset was significantly associated with an individual's likelihood of presenting 
with several symptoms in the literature cohort. Older age at onset is associated with elevated rates 
of ischemic stroke (p = 0·0003, OR for developing symptom = 1·09 per 1-year increase in age of 
onset, 95% CI [1·04, 1·14]) and decreased rates of myoclonus (p = 0·0007, OR = 0·93, 95% CI 
[0·90, 0·97]), seizures (p = 0·0018, OR = 0·95, 95% CI [0·92, 0 ·98]), corticobulbar deficits (p = 
0·0012, OR = 0·91, 95% CI [0·86, 0·96]), and cerebellar ataxia (p = 0·0002, OR = 0·82, 95% CI 
[0·74, 0·91]) (figure 3).  
 
For the DIAN–OBS cohort, prevalence rates were only calculated for PSEN1 and APP, as there 
were too few symptomatic individuals with PSEN2 mutations. After excluding Dutch mutation 
carriers, several symptoms were notably absent from APP mutation carriers in the DIAN–OBS 
population: new-onset seizures, stroke, and corticobulbar deficits.  
 
Finally, we compared PSEN1 mutation carriers before and after codon 200 in the DIAN–OBS and 
literature groups, and compared the rates at which they demonstrated behavioral and neurological 
deficits (figures 4 and 5). In the literature group, PSEN1 mutations after codon 200 were more 
likely to be associated with spasticity (21/215 (9·8%) vs. 89/332 (26·8%), p < 0·0001). However, 
in the DIAN–OBS cohort, there was no significant difference in the prevalence of any symptom 
for mutations before or after codon 200. Interestingly, mirroring recent findings by Ryan et al,5 the 
pre-codon 200 population in the DIAN–OBS cohort has a significantly earlier age of onset than 
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the post-codon 200 population (37·3(6.9) vs. 45·0(8·1), p < 0·0001), a difference that was not seen 
in the literature population (42·8(10·4) vs. 43·7(8·3), p = 0·319).  
 
Discussion 
 
In the DIAN–OBS, we found that the most frequently reported non-amnestic manifestations were 
cognitive, including visual agnosia, aphasia, and behavioral changes. However, in our meta-
analysis of the literature, we found moderate rates of motor symptoms and seizures and lower rates 
in the DIAN–OBS. Interestingly, younger age of onset and more advanced stages of disease were 
related to a higher frequency of non-cognitive clinical features. A larger prospective cohort study 
now reports that a significant minority, 16% of the individuals with ADAD had non-amnestic 
cognitive phenotypes and about 25% had atypical neurologic symptoms in addition to an amnestic 
phenotype [Ryan et. Al 2016 Lancet Neurology], suggesting that in cases with unusual neurologic 
manifestations, genetic counseling and testing may be warranted. 
 
One potential interpretation of these findings is that compared to clinical data collected 
prospectively in DIAN–OBS, case reports may overestimate the prevalence of non-cognitive 
neurologic manifestations (eg, myoclonus and seizures), while underestimating cognitive 
neurologic manifestations (eg, visual agnosia, aphasia, and behavioral/personality changes). Two 
sources of bias that could contribute include measurement bias and ascertainment bias. The DIAN–
OBS prospective cohort study complements the literature reports to help account for these biases. 
Likewise, the literature reports provide a broader understanding with longer duration follow-up 
and more advanced disease.  
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With regards to measurement bias, our study demonstrates the impact of having systematic 
protocols in observational cohort studies (supplemental table 1). By employing uniform study 
procedures, symptoms are consistently identified, such as non-amnestic cognitive symptoms. The 
DIAN–OBS prospective and uniform assessments of earliest symptom onset may account for the 
earlier age of onset reported in the DIAN–OBS cohort. However, the limited follow up period in 
DIAN–OBS compared to literature likely resulted in a lower prevalence of certain symptoms such 
as seizures and myoclonus that were found to be higher in the published literature cohort, due to 
higher symptom prevalence at later stages of the disease (figure 3b). With further follow-up, the 
DIAN–OBS will be positioned to accurately prospectively measure symptoms with more advanced 
disease. 
 
Non-amnestic cognitive phenotypes are more commonly reported in SAD and include language 
variants, executive-frontal variants and a visuoperceptual variant- posterior cortical atrophy 
(PCA)13. In general, these focal variants have been reported less, in ADAD14,15. Importantly, in 
SAD these variants appear to occur more frequently at younger ages of onset. A recent study found 
an odds ratio of greater than 5–12 for non-amnestic cognitive impairment in those with AD in the 
6th decade versus those in the 9th decade.16 Similar to the common SAD presentation in DIAN-
OBS the majority of subjects had amnestic impairments as the first presenting symptom2.  
 
The current literature indicates that when non-amnestic variants are present, the symptoms are 
related to NFT pathology and not Aβ plaques17. Thus, in both SAD and DIAD, clinical cognitive 
symptoms appear to be more related to tau pathology18.  
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We sought to determine the age, disease stage, mutation, and other genetic effects on the 
manifestation of symptoms. Interestingly, age of onset appears to significantly impact the risk of 
neurologic manifestations. For example, in the literature cases, individuals who begin to decline 
at a younger age are more likely to develop myoclonus and seizures than their older age at onset 
counterparts. In contrast, stroke and hemorrhage were associated with older ages of onset. 
 
However, the DIAN–OBS cohort showed lower overall incidences of myoclonus and seizures than 
the literature group, possibly due to milder stages of disease (figure 3b). In the DIAN-OBS study, 
we found a trend of increasing prevalence of all symptoms including cognitive symptoms such as 
apraxia, visual agnosia, and non-cognitive symptoms including such as seizures, myoclonus, 
spasticity, cerebellar ataxia, and parkinsonism, at later stages of disease. Several previous studies 
suggest that for individuals with ADAD, seizures are correlated with earlier age of onset and more 
severe disease19-23. Our work focusing on the published literature supports the importance of the 
age of onset as it relates to myoclonus and seizures, and now adds the association of disease 
duration and symptom frequency from the DIAN–OBS. In the sporadic Alzheimer population, 
there is also evidence to support that an earlier age of onset is associated with an increased risk of 
seizures24,25. 
 
In order to account for other genetic or environmental factors that may influence disease 
presentation within a pedigree, we included family membership as a covariate in our analysis of 
symptom prevalence in PSEN1, PSEN2, and APP mutation carriers as reported in the literature. 
We demonstrated some differences between APP, PSEN1, and PSEN2 mutations in the prevalence 
19 
 
of certain symptoms (eg, in myoclonus and spasticity for PSEN1). Further, we found a propensity 
for APP mutation carriers to present with stroke or hemorrhage. It has been previously reported 
that PSEN1 mutations before codon 200 are pathologically different from those after codon 200, 
likely due to differences in the severity of amyloid angiopathy and rates of amyloid deposition26. 
However, aside from spasticity, there are no apparent differences in symptom prevalence between 
PSEN1 pre-codon 200 and post-codon 200 mutations (figure 4). Significant heterogeneity exists 
within the pre- and post-codon 200 PSEN1 mutation groups. Additionally, within PSEN1, there is 
a notable paucity of pathogenic mutations between codon 290-350 (figure 5), which gives rise to 
three possibilities – that mutations in this region are asymptomatic, that they are lethal, or that 
these regions have intrinsically lower rates of mutation.  
 
Although APOE ε4 is a major risk factor for SAD27, the evidence for APOE's effect on ADAD 
presentation is less clear7,28-30. Our current analysis of symptomatic mutation carriers is too small 
for constructing a model that includes APOE status as a co–variate in addition to age of onset, 
pedigree membership, and mutated ADAD gene.  
 
The strength of the DIAN Observational Study is that it is a prospective cohort study of many 
mutations and families implemented with uniform standard assessments. However, limitations of 
the DIAN–OBS include the relatively small number of symptomatic participants, with 107 
individuals in various stages of dementia as determined by our inclusion criteria. Consequently, 
we could not construct a model that simultaneously takes into account factors that may influence 
disease course such as mutated gene, duration of follow up, and APOE genotype. Further, the 
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DIAN–OBS dataset includes few severe stages of disease with the average stage at moderate 
dementia (mean MMSE 21.0 (10.9)).  
 
Accurately determining the prevalence of specific clinical and neurological signs and symptoms 
is important for defining a clinical disease, understanding its prognosis and impact on patients, and 
for informing the conduct of clinical research. A more complete understanding of cognitive and 
other neurological manifestations of ADAD will allow for improvements in diagnosis, prognosis, 
and management, as well as the design of research studies in this unique and important population. 
Future studies will be able to compare the clinical presentation of ADAD patients with sporadic 
Alzheimer’s disease in greater detail, leading the field toward a deeper understanding of their 
shared clinical manifestations which will be critical to accurately interpret the findings of ongoing 
treatment trials in each disorder. 
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Research in context 
 
Evidence before this study 
 
We reviewed publications up through January 27, 2015 cited in the AD/FTD Mutation Database 
and the Alzheimer Research Forum database, and searched PubMed identifying 189 peer-reviewed 
journal articles which reported individual-level data on age of symptom onset, disease course from 
onset to death, and the presence of fourteen neurological findings previously reported to be 
associated with ADAD. There is a large body of literature providing phenotypic information on 
specific autosomal dominant Alzheimer disease (ADAD) mutations. Over 170 of these reports are 
on a small number of subjects or families across a wide spectrum of clinical severity. These reports 
suggested a relatively high prevalence of non-cognitive neurologic manifestations including 
behavioral, motor symptoms, and seizures which may be further influenced by specific gene 
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mutation. However, there are less than 7 reports of large cohorts from single centers and no 
compiled individual level data review. 
 
 
Added value of this study 
 
Our literature based dataset includes 1228 affected individuals from literature reports, with detailed 
clinical descriptions of disease course available for 753 of this group with an average of 8 years of 
follow-up. The DIAN-OBS dataset included 107 symptomatic individuals with detailed clinical 
data from an ongoing, observational study with an average of over 3 years of follow-up. From 
these two datasets we were able to report descriptive statistics, comparisons of prevalence between 
the DIAN study and the published data base, as well as determine correlations between clinical 
features and gene mutation type and position in both data sets. This study provides one of the 
largest and most diverse collections of prospectively followed, symptomatic, ADAD populations 
to provide more accurate estimates of non-amnestic clinical features. 
 
With the large number of PSEN1 mutations we were also able to explore whether atypical clinical 
features were more commonly associated with specific codon position, as has been suggested 
previously. However, in the DIAN population we found no clear associations of clinical features 
with PSEN1 codon position.  
 
 
Implications of available evidence 
23 
 
 
This study indicates that the prevalence of atypical clinical features in ADAD is low and may have 
been overestimated in the published literature. Non-cognitive neurologic symptoms of AD appear 
to affect the minority of ADAD mutation carriers, suggesting that the mutations are not the major 
factor for presentation of non-cognitive neurologic manifestations of AD. The factors that 
influence the presence of neurological symptoms include unidentified genetic and environmental 
factors with some impact from the age of onset, stage of disease and type of mutation. Further, 
non-amnestic cognitive impairment is common in ADAD, similar to sporadic AD. As ADAD has 
provided a wealth of understanding of AD pathophysiologic processes, future work comparing 
ADAD with sporadic AD will lead to a better understanding of both sporadic and dominantly 
inherited AD.  
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Table 1: Study population      
  
 
Literature DIAN  
N Total 1228 107  
  
Clinical 
descriptions 753 107 
 
Sex M 34·7% 43·9%  
  F 38·0% 56·1%  
  Unknown 27·3% -  
Gene PSEN1 74·2% 80·4%  
  PSEN2 5·0% 1·9%  
  APP 20·8% 17·7%  
Age of symptom 
onset Mean 46·0 42·9 
p = 0·0004  
  SD 10·5 8·17  
Follow up (years) Mean 8·33 3·93 p < 0·0001 
  SD 4·59 3·18  
CDR Mean - 1·05  
 
SD - 0·79  
CDR-SB Mean - 5·39  
 
SD - 5·06  
MMSE Mean - 20.98  
 
SD - 10.92  
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Figure 1. Combined symptom prevalence in reported and prospectively observed ADAD. 
Included are all individuals with detailed clinical descriptions from the DIAN prospective 
observational study and the ADAD literature (N = 107 and 753, respectively). Error bars are 
95% confidence intervals.  
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Table 2: Comparisons of symptom prevalence between DIAN and Literature 
  
Frequency 
(DIAN) 95% CI 
Frequency 
(Literature) 95% CI p-value 
Parkinsonism 0·11 [0·053, 0·17] 0·12 [0·10, 0·15] 0·71 
Myoclonus 0·094 [0·038, 0·15] 0·19 [0·17, 0·22] 0·012 
Seizures 0·028 [0, 0·059] 0·20 [0·17, 0·23] <0·0001 
Spasticity 0·094 [0·038, 0·15] 0·15 [0·12, 0·18] 0·12 
Corticobulbar 
deficits 0·028 [0, 0·059] 0·081 [0·06, 0·10] 0·051 
Cerebellar ataxia 0·149 [0·082, 0·22] 0·031 
[0·018, 
0·043] <0·0001 
Aphasia 0·53 [0·44, 0·63] 0·23 [0·20, 0·26] <0·0001 
Apraxia 0·075 [0·025, 0·12] 0·12 [0·094, 0·14] 0·19 
Visual agnosia 0·55 [0·46, 0·65] 0·056 
[0·039, 
0·072] <0·0001 
Hallucinations 0·065 [0·019, 0·11] 0·056 
[0·039, 
0·072] 0·69 
Behavior/Personality 
changes 0·61 [0·51, 0·70] 0·32 [0·28, 0·35] <0·0001 
Hemorrhagic stroke 0 - 0·041 
[0·027, 
0·055] - 
Ischemic stroke 0 - 0·042 
[0·028, 
0·057] - 
N 107  753   
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Figure 2. Comparison of reported symptom prevalence in APP, PSEN1, and PSEN2 mutation 
carriers. (Literature - N = 171 for APP, 547 for PSEN1, 35 for PSEN2; DIAN-OBS - N = 19 (APP), 
86 (PSEN1), 2 (PSEN2)). Rates for PSEN2 carriers in DIAN-OBS were not calculated as there 
were only two symptomatic individuals in that group. Although significant variability in 
symptom prevalence is observed between mutations in the three genes in the reported 
literature, there were few differences between APP and PSEN1 in the DIAN-OBS cohort. Error 
bars shown are 95% confidence intervals. 
28 
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Figure 3a. Comparison of reported prevalence of cognitive and non-cognitive neurological 
symptoms in ADAD by age of disease onset. Individuals were considered symptomatic if they 
developed the symptom at any point in their disease course. Solid lines represent symptoms 
for which a one-year increase in age of onset is associated with a statistically significant 
change in risk. 
Figure 3b. Symptom prevalence by CDR Sum of Box score, in DIAN-OBS. All cognitive 
symptoms and most non-cognitive symptoms (except corticobulbar deficits) increase in 
prevalence as the clinical stage worsens. Total CDR-SB = CDR sum of boxes + 
supplemental sum of boxes, possible scores 0-24. As all individuals included in the DIAN-
OBS analysis are symptomatic, the lowest total CDR-SB in this group is 0.5. 
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Figure 4. Comparison of symptom prevalence for PSEN1 mutations before and after codon 200 
in literature and DIAN-OBS cohort. (Literature - N = 215, 332; DIAN-OBS - N = 24, 62).  
 
ALTERNATE FIGURE 4 
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Figure 5. Distribution of known pathogenic PSEN1 mutations in literature and the rates at 
which carriers demonstrated spasticity in their disease course.  
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Supplemental Table 1. Symptoms in the DIAN cohort, with UDS terms and descriptions 
  
Symptom Section Description 
Parkinsonism UDS B9: Clinician Judgment of 
Symptoms 
12a. If there were changes in motor function, were these suggestive of 
parkinsonism? 
Myoclonus UDS B3: UPDRS; Neurological 
Exam 
 
Mentioned specifically in commentary 
Seizures UDS A5: Subject Health 
History 
a. Seizures (recent/active only) 
Spasticity UDS B3: UPDRS; Neurological 
exam 
 
Mentioned specifically in commentary 
Corticobulbar deficits UDS B3: UPDRS; Neurological 
Exam 
 
Mentioned specifically in commentary 
Cerebellar ataxia UDS B3: UPDRS Mentioned specifically in commentary 
 
Neurological Exam 
 
Impaired finger-nose-finger or heel-shin, excluding instances of limited 
comprehension, limb weakness, or confounding apraxia 
 
Aphasia UDS B9: Clinician Judgment of 
Symptoms 
4c. Language (For example, does s/he have hesitant speech; have trouble 
finding words; use inappropriate words without self-correction?) 
Apraxia UDS B3: UPDRS; Neurological 
exam 
 
Mentioned specifically in commentary 
Visual agnosia UDS B9: Clinician Judgment of 
Symptoms 
4d. Visuospatial function (Difficulty interpreting visual stimuli and finding 
his/her way around.) 
Hallucinations UDS B9: Clinician Judgment of 
Symptoms 
7c. 1) Psychosis: Visual hallucinations 
  UDS B9: Clinician Judgment of 
Symptoms 
7c. 2) Psychosis: Auditory hallucinations 
Behavioral/personality 
changes 
UDS B9: Clinician Judgment of 
Symptoms 
7d. Disinhibition (Does the subject use inappropriate coarse language or 
exhibit inappropriate speech or behaviors in public or in the home? Does 
s/he talk personally to strangers or have disregard for personal hygiene?) 
  UDS B9: Clinician Judgment of 
Symptoms 
7e. Irritability (Does the subject overreact, such as shouting at family 
members or others?) 
  UDS B9: Clinician Judgment of 
Symptoms 
7f. Agitation (Does the subject have trouble sitting still; does s/he shout, hit, 
and/or kick?) 
  UDS B9: Clinician Judgment of 
Symptoms 
7g. Personality change (Does the subject exhibit bizarre behavior or behavior 
uncharacteristic of the subject, such as unusual collecting, suspiciousness 
[without delusions], unusual dress, or dietary changes? Does the subject fail 
to take other's feelings into account?) 
Stroke UDS B2: HIS and CVD 6. History of stroke (recent/active only) 
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In our analysis, we recorded each individual as exhibiting a symptom if the manuscript in which 
they are found mentioned the symptom in connection with dementia in a detailed clinical 
description of the course of disease. For DIAN, some of these symptoms are covered by single 
variables in the UDS (supplemental table 1), such as parkinsonism, seizures, visual agnosia, 
aphasia, and stroke, while others were derived from a combination of several variables, such as 
hallucinations (combined visual and auditory), cerebellar ataxia (abnormal finger-nose-finger 
and/or heel-shin exam, or clinical report), and behavioral changes (disinhibition, agitation, 
irritation, and other personality changes). A third group (myoclonus, spasticity, corticobulbar 
deficits, and apraxia) did not have specific variables associated but were tested and searched for 
in the neurological exam conducted during each visit and the UPDRS (UDS B3). Differences in 
how variables are obtained present a challenge to interpretation, as symptoms specifically 
enumerated in the UDS may be more consistently detected and documented by clinicians. This 
appears to be the case for visual agnosia and behavioral/psychiatric changes, which are common 
in both sporadic and dominantly inherited Alzheimer’s disease (figure 1). The language used in 
the UDS may also influence the rate of detection. For instance, aphasia in the DIAN group is 
determined using UDS B9 4c, which is a clinician judgment of symptoms including "hesitant 
speech, trouble finding words, and using inappropriate words without self correction", all of which 
may reflect word-finding difficulty which can be a consequence of memory impairment. 
Alternatively, the more stringent category of primary progressive aphasia is included as a possible 
clinician diagnosis (UDS D10), but so far there has not been a case documented as such in the 
DIAN cohort as of December 2014. Consequently, the higher prevalence of aphasia in the DIAN 
population may be an artifact of how the UDS question is constructed. Likewise, in the published 
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literature it is likely that the predominant symptom at the time of clinical presentation is most 
likely to be reported. This would result in a tendency to under report symptoms such as language 
disorders, which are very common with disease progression in all forms of Alzheimer’s disease.  
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